company background image
6030

Gan & Lee Pharmaceuticals SHSE:603087 Stock Report

Last Price

CN¥33.10

Market Cap

CN¥18.6b

7D

-5.8%

1Y

-57.5%

Updated

24 Sep, 2022

Data

Company Financials +
603087 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance2/6
Financial Health6/6
Dividends2/6

603087 Stock Overview

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin analogues primarily in China.

Gan & Lee Pharmaceuticals. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gan & Lee Pharmaceuticals
Historical stock prices
Current Share PriceCN¥33.10
52 Week HighCN¥83.38
52 Week LowCN¥32.88
Beta3.21
1 Month Change-10.10%
3 Month Change-29.26%
1 Year Change-57.46%
3 Year Changen/a
5 Year Changen/a
Change since IPO-49.18%

Recent News & Updates

Shareholder Returns

603087CN BiotechsCN Market
7D-5.8%-4.7%-1.9%
1Y-57.5%-35.5%-18.6%

Return vs Industry: 603087 underperformed the CN Biotechs industry which returned -35.5% over the past year.

Return vs Market: 603087 underperformed the CN Market which returned -18.6% over the past year.

Price Volatility

Is 603087's price volatile compared to industry and market?
603087 volatility
603087 Average Weekly Movement4.9%
Biotechs Industry Average Movement4.8%
Market Average Movement5.8%
10% most volatile stocks in CN Market9.3%
10% least volatile stocks in CN Market3.7%

Stable Share Price: 603087 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 603087's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19983,278n/ahttps://www.ganlee.com

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin analogues primarily in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro; Raplin, an insulin aspart injection; Raplin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection, as well as medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd.

Gan & Lee Pharmaceuticals. Fundamentals Summary

How do Gan & Lee Pharmaceuticals's earnings and revenue compare to its market cap?
603087 fundamental statistics
Market CapCN¥18.59b
Earnings (TTM)CN¥882.38m
Revenue (TTM)CN¥2.97b

21.1x

P/E Ratio

6.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
603087 income statement (TTM)
RevenueCN¥2.97b
Cost of RevenueCN¥380.96m
Gross ProfitCN¥2.59b
Other ExpensesCN¥1.71b
EarningsCN¥882.38m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.57
Gross Margin87.18%
Net Profit Margin29.70%
Debt/Equity Ratio0%

How did 603087 perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

19%

Payout Ratio